Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL; HBV 99-01 Study Group. Flink HJ, et al. Among authors: karayalcin s. Am J Gastroenterol. 2006 Nov;101(11):2523-9. doi: 10.1111/j.1572-0241.2006.00812.x. Epub 2006 Oct 4. Am J Gastroenterol. 2006. PMID: 17029610 Clinical Trial.
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.
Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA; International Lamivudine Investigator Group. Schiff ER, et al. Among authors: karayalcin s. J Hepatol. 2003 Jun;38(6):818-26. doi: 10.1016/s0168-8278(03)00076-x. J Hepatol. 2003. PMID: 12763376 Clinical Trial.
YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.
Bozdayi AM, Uzunalimoğlu O, Türkyilmaz AR, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, Bozkaya H, Karayalçin S, Yurdaydin C, Schinazi RF. Bozdayi AM, et al. Among authors: karayalcin s. J Viral Hepat. 2003 Jul;10(4):256-65. doi: 10.1046/j.1365-2893.2003.00435.x. J Viral Hepat. 2003. PMID: 12823591 Clinical Trial.
Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
Idilman R, Arat M, Soydan E, Törüner M, Soykan I, Akbulut H, Arslan O, Ozcan M, Türkyilmaz AR, Bozdayi M, Karayalçin S, Van Thiel DH, Ozden A, Beksaç M, Akan H. Idilman R, et al. Among authors: karayalcin s. J Viral Hepat. 2004 Mar;11(2):141-7. doi: 10.1046/j.1365-2893.2003.00479.x. J Viral Hepat. 2004. PMID: 14996349 Clinical Trial.
40 results